Drug Trial Radar · NCT07105098
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
284
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Conditions
- Schizophrenia
Interventions
NBI-1117568Drug
NBI-1117568 will be administered per schedule specified in the arm description.
PlaceboDrug
Placebo will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5Time frame: Baseline, Week 5
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Little Rock, Arkansas · Recruiting
Neurocrine Clinical Site
Culver City, California · Recruiting
Neurocrine Clinical Site
Garden Grove, California · Recruiting
Neurocrine Clinical Site
Riverside, California · Recruiting
Neurocrine Clinical Site
Hollywood, Florida · Recruiting
Neurocrine Clinical Site
Atlanta, Georgia · Completed
Neurocrine Clinical Site
North Canton, Ohio · Recruiting
Neurocrine Clinical Site
Pleven, Bulgaria · Recruiting
Neurocrine Clinical Site
Sliven, Bulgaria · Recruiting
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria · Withdrawn
Neurocrine Clinical Site
Vratsa, Bulgaria · Recruiting
Neurocrine Clinical Site
Budapest, Hungary · Recruiting
Neurocrine Clinical Site
Gyöngyös, Hungary · Recruiting
Neurocrine Clinical Site
Győr, Hungary · Completed
Neurocrine Clinical Site
Brasov, Romania · Recruiting
Neurocrine Clinical Site
Brasov, Romania · Recruiting
Neurocrine Clinical Site
Bucharest, Romania · Completed
Neurocrine Clinical Site
Belgrade, Serbia · Withdrawn
Neurocrine Clinical Site
Gornja Toponica, Serbia · Recruiting
Neurocrine Clinical Site
Kragujevac, Serbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.